[1]
|
SIEGEL RL,MILLER KD,JEMAL A.Cancer Statistics,2017[J].CA Cancer J Clin,2017,67(1):7. |
[2]
|
BERTUCCI F,FINETTI P,CERVERA N,et al.How basal are triple-negative breast cancers?[J].Int J Cancer,2008,123(1):236. |
[3]
|
GONZALEZ-ANGULO AM,TIMMS KM,LIU S,et al.Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer[J].Clin Cancer Res,2011,17(5):1082. |
[4]
|
MILLIKAN RC,NEWMAN B,TSE CK,et al.Epidemiology of basal-like breast cancer[J].Breast Cancer Res Treat,2008,109(1):123. |
[5]
|
BERRY DA,CIRRINCIONE C,HENDERSON IC,et al.Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer[J].JAMA,2006,295(14):1658. |
[6]
|
FRANCISZKIEWICZ K,BOISSONNAS A,BOUTET M,et al.Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response[J].Cancer Res,2012,72(24):6325. |
[7]
|
GUNN MD,NGO VN,ANSEL KM,et al.A B-cell-homing chemokine made in lymphoid follicles activates Burkitt's lymphoma receptor-1[J].Nature,1998,391(6669):799. |
[8]
|
QI XW,XIA SH,YIN Y,et al.Expression features of CXCR5 and its ligand,CXCL13 associated with poor prognosis of advanced colorectal cancer[J].Eur Rev Med Pharmacol Sci,2014,18(13):1916. |
[9]
|
SINGH R,GUPTA P,KLOECKER GH,et al.Expression and clinical significance of CXCR5/CXCL13 in human nonsmall cell lung carcinoma[J].Int J Oncol,2014,45(6):2232. |
[10]
|
WEI Y,LIN C,LI H,et al.CXCL13 expression is prognostic and predictive for postoperative adjuvant chemotherapy benefit in patients with gastric cancer[J].Cancer Immunol Immunother,2018,67(2):261. |
[11]
|
BISWAS S,SENGUPTA S,ROY CHOWDHURY S,et al.Erratum to:CXCL13-CXCR5 co-expression regulates epithelial to mesenchymal transition of breast cancer cells during lymph node metastasis[J].Breast Cancer Res Treat,2016,155(3):615. |
[12]
|
EBERT LM,SCHAERLI P,MOSER B.Chemokine-mediated control of T cell traffic in lymphoid and peripheral tissues[J].Mol Immunol,2005,42(7):799. |
[13]
|
RAZIS E,KALOGERAS KT,KOTOULA V,et al.Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression[J].Clin Breast Cancer,2012,12(3):183. |
[14]
|
CHEN L,HUANG Z,YAO G,et al.The expression of CXCL13 and its relation to unfavorable clinical characteristics in young breast cancer[J].J Transl Med,2015,13(1):68. |